501 related articles for article (PubMed ID: 30798468)
21. Update in adrenocortical carcinoma.
Fassnacht M; Kroiss M; Allolio B
J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
[TBL] [Abstract][Full Text] [Related]
22. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
[TBL] [Abstract][Full Text] [Related]
23. Next-generation therapies for adrenocortical carcinoma.
Altieri B; Ronchi CL; Kroiss M; Fassnacht M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101434. PubMed ID: 32622829
[TBL] [Abstract][Full Text] [Related]
24. Metastatic Adrenal Cortical Carcinoma Responding to Octreotide: A Case Report.
Wang X; Zhou N; Xiao Y; Zhu W; Bai C; Zhao L
Oncologist; 2019 Aug; 24(8):e793-e797. PubMed ID: 31073023
[TBL] [Abstract][Full Text] [Related]
25. Current Prospects for Adrenocortical Carcinoma Pharmacotherapy.
Ławnicka H
Recent Pat Anticancer Drug Discov; 2023; 18(1):29-37. PubMed ID: 36482727
[TBL] [Abstract][Full Text] [Related]
26. Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma.
Ohmoto A; Shigematsu Y; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Komai Y; Numao N; Yuasa T; Yonese J; Tomomatsu J; Inamura K; Takahashi S
Endocr J; 2021 Dec; 68(12):1383-1390. PubMed ID: 34176818
[TBL] [Abstract][Full Text] [Related]
27. Advanced Adrenocortical Carcinoma: Current Perspectives on Medical Treatment.
Araújo AN; Bugalho MJ
Horm Metab Res; 2021 May; 53(5):285-292. PubMed ID: 33962475
[TBL] [Abstract][Full Text] [Related]
28. In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures
Fragni M; Palma Lopez LP; Rossini E; Abate A; Cosentini D; Salvi V; Vezzoli S; Poliani PL; Bosisio D; Hantel C; Tiberio GAM; Grisanti S; Memo M; Terzolo M; Berruti A; Sigala S
Mol Cell Endocrinol; 2019 Dec; 498():110585. PubMed ID: 31536779
[TBL] [Abstract][Full Text] [Related]
29. MECHANISMS OF ENDOCRINOLOGY: Cell cycle regulation in adrenocortical carcinoma.
Pereira SS; Monteiro MP; Bourdeau I; Lacroix A; Pignatelli D
Eur J Endocrinol; 2018 Aug; 179(2):R95-R110. PubMed ID: 29773584
[TBL] [Abstract][Full Text] [Related]
30. Approach to the patient with adrenocortical carcinoma.
Lacroix A
J Clin Endocrinol Metab; 2010 Nov; 95(11):4812-22. PubMed ID: 21051577
[TBL] [Abstract][Full Text] [Related]
31. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Gay L; Presta MJ; Sheehan CE; Ali SM; Elvin JA; Labrecque E; Hiemstra C; Buell J; Otto GA; Yelensky R; Lipson D; Morosini D; Chmielecki J; Miller VA; Stephens PJ
J Clin Pathol; 2014 Nov; 67(11):968-73. PubMed ID: 25078331
[TBL] [Abstract][Full Text] [Related]
32. The next generation of therapies for adrenocortical cancers.
Kirschner LS
Trends Endocrinol Metab; 2012 Jul; 23(7):343-50. PubMed ID: 22626690
[TBL] [Abstract][Full Text] [Related]
33. Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease.
Libé R; Huillard O
Cancer Treat Res Commun; 2023; 37():100759. PubMed ID: 37690343
[TBL] [Abstract][Full Text] [Related]
34. Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma.
Tierney JF; Vogle A; Finnerty B; Zarnegar R; Ghai R; Gattuso P; Fahey TJ; Keutgen XM
J Surg Res; 2020 Dec; 256():90-95. PubMed ID: 32683062
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological profile and effects of mitotane in adrenocortical carcinoma.
Corso CR; Acco A; Bach C; Bonatto SJR; de Figueiredo BC; de Souza LM
Br J Clin Pharmacol; 2021 Jul; 87(7):2698-2710. PubMed ID: 33382119
[TBL] [Abstract][Full Text] [Related]
36. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
[TBL] [Abstract][Full Text] [Related]
37. Adrenocortical Carcinoma: A Clinician's Perspective.
Elfiky A
Surg Pathol Clin; 2015 Dec; 8(4):751-4. PubMed ID: 26612225
[TBL] [Abstract][Full Text] [Related]
38. [Adrenocortical carcinomas: therapeutic advances in 2011].
Grunenwald S; Caron P
Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S8-S14. PubMed ID: 22008276
[TBL] [Abstract][Full Text] [Related]
39. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.
Lang J; Capasso A; Jordan KR; French JD; Kar A; Bagby SM; Barbee J; Yacob BW; Head LS; Tompkins KD; Freed BM; Somerset H; Clark TJ; Pitts TM; Messersmith WA; Eckhardt SG; Wierman ME; Leong S; Kiseljak-Vassiliades K
J Clin Endocrinol Metab; 2020 Jan; 105(1):26-42. PubMed ID: 31513709
[TBL] [Abstract][Full Text] [Related]
40. Adrenocortical Carcinoma Steroid Profiles:
Muzzi JCD; Magno JM; Cardoso MA; de Moura J; Castro MAA; Figueiredo BC
Front Endocrinol (Lausanne); 2021; 12():672319. PubMed ID: 34194394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
